Article

HIV Dolutegravir Resistance and Multiclass Failure in Mozambique: Findings from a Real-World Cohort

2025-05-22

Abstract excerpt

<h4>Background</h4> Dolutegravir (DTG) is the anchor drug of the first-line agent for HIV treatment globally, including low- and middle-income countries. Although clinical trials report low rates of integrase inhibitor resistance, real-world data from sub-Saharan Africa suggest a different scenario. We aimed to assess the prevalence and patterns of DTG resistance in Mozambique, building on prior preliminary findin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3819c9c8-014a-5b45-a050-dfb6c7db1ef3
DOI: 10.1101/2025.05.19.25327901

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

HIV Dolutegravir Resistance and Multiclass Failure in Mozambique: Findings from a Real-World CohortDOI 10.1101/2025.05.19.25327901Read

Virological Outcomes and Dolutegravir Resistance Mutations in HIV-infected Patients: A Multicenter Retrospective Cohort Study in MozambiqueSemantic proximity Read

HIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studiesSemantic proximity Read

Brief communication: virological outcomes and dolutegravir resistance mutations in HIV-infected patients: a multicenter retrospective cohort study in Mozambique.Semantic proximity Read

Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi’s National HIV Treatment ProgramSemantic proximity Read

HIV-1 Antiretroviral Drug Resistance in Mozambique: A Systematic Review and Meta-Analysis.Semantic proximity Read

Molecular Epidemiology and Trends in HIV-1 Transmitted Drug Resistance in Mozambique 1999-2018.Semantic proximity Read

Worrisome Emergence of Pan-INSTI Resistance: A Systematic Scoping Review of Dolutegravir Resistance in INSTI-Naïve Patients Post-Therapy FailureSemantic proximity Read

HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre longitudinal study (DTG RESIST)Semantic proximity Read

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.Semantic proximity Read

A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings.Semantic proximity Read

Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique.Semantic proximity Read

Brief Report: Resistance to Dolutegravir in Treatment-Experienced Patients in South Africa: A Retrospective Cohort StudySemantic proximity Read